Search

Your search keyword '"Lim, Yeong Jer"' showing total 14 results
Start Over Author "Lim, Yeong Jer"
14 results on '"Lim, Yeong Jer"'

2. Immunogenicity of COVID‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.

Author

Lim, Yeong Jer, Ward, Victoria, Brown, Anthony, Phillips, Eloise, Kronsteiner, Barbara, Malone, Tom, Jennings, Daisy, Healy, Saoirse, Longet, Stephanie, James, Timothy, Thomson, Paul, Farrell, Liam, Oates, Melanie, Jackson, Richard, Morrison, Andrew, Burns, Matthew, Carroll, Miles, Klenerman, Paul, Turtle, Lance, and Naisbitt, Dean

Subjects
*FOLLICULAR lymphoma, *VACCINE immunogenicity, *ANTIBODY formation, *T cells, *IMMUNE response
Abstract

Summary: Immune responses to primary COVID‐19 vaccination were investigated in 58 patients with follicular lymphoma (FL) as part of the PETReA trial of frontline therapy (EudraCT 2016–004010‐10). COVID‐19 vaccines (BNT162b2 or ChAdOx1) were administered before, during or after cytoreductive treatment comprising rituximab (depletes B cells) and either bendamustine (depletes CD4+ T cells) or cyclophosphamide‐based chemotherapy. Blood samples obtained after vaccine doses 1 and 2 (V1, V2) were analysed for antibodies and T cells reactive to the SARS‐CoV‐2 spike protein using the Abbott Architect and interferon‐gamma ELISpot assays respectively. Compared to 149 healthy controls, patients with FL exhibited lower antibody but preserved T‐cell responses. Within the FL cohort, multivariable analysis identified low pre‐treatment serum IgA levels and V2 administration during induction or maintenance treatment as independent determinants of lower antibody and higher T‐cell responses, and bendamustine and high/intermediate FLIPI‐2 score as additional determinants of a lower antibody response. Several clinical scenarios were identified where dichotomous immune responses were estimated with >95% confidence based on combinations of predictive variables. In conclusion, the immunogenicity of COVID‐19 vaccines in FL patients is influenced by multiple disease‐ and treatment‐related factors, among which B‐cell depletion showed differential effects on antibody and T‐cell responses. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. COVID‐19 outcomes in haematopoietic cell transplant recipients : A systematic review and meta‐analysis

Author

Lim, Yeong Jer, Khan, Umair, Karpha, Indrani, Ross, Andrew, Saif, Muhammad, Remberger, Mats, Kalakonda, Nagesh, Pettitt, Andrew R., Floisand, Yngvar, Lim, Yeong Jer, Khan, Umair, Karpha, Indrani, Ross, Andrew, Saif, Muhammad, Remberger, Mats, Kalakonda, Nagesh, Pettitt, Andrew R., and Floisand, Yngvar

Abstract

Up-to-date information on coronavirus disease 2019 (COVID-19) outcomes and risk factors in haematopoietic cell transplantation (HCT) recipients is required to inform on decisions about cancer treatment and COVID-19 mitigation strategies. We performed a meta-analysis to address this knowledge gap. All studies with at least five patients who reported COVID-19-related deaths in HCT recipients were included. The primary outcome was COVID-19-related death. Secondary outcomes were COVID-19-related mechanical ventilation (MV) and intensive care unit (ITU) admission. The cumulative COVID-19-related death rate among HCT recipients was 21% (95% confidence interval [CI] 18%–24%), while MV and ITU admission rates were 14% (95% CI 11%–17%) and 18% (95% CI 14%–22%), respectively. Subgroup analysis showed higher death rates in patients who developed COVID-19 within 12 months of HCT (risk ratio [RR] 1.82, 95% CI 1.09–3.03), within 6 months of receiving immunosuppressant drugs (RR 2.11, 95% CI 1.38–3.20) or in the context of active graft-versus-host disease (RR 2.38, 95% CI 1.10–5.16). Our findings support the idea that HCT should remain an integral part of cancer treatment during the COVID-19 pandemic but also highlight the need to prioritise preventative measures in those patients who are at increased risk of adverse COVID-19 outcomes.

Published
2022
Full Text
View/download PDF

8. Autologous Hematopoietic Stem Cell Transplantation for Behçet’s Disease: A Retrospective Survey of Patients Treated in Europe, on Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation

Author

Puyade, Mathieu, primary, Patel, Amit, additional, Lim, Yeong Jer, additional, Blank, Norbert, additional, Badoglio, Manuela, additional, Gualandi, Francesca, additional, Ma, David D., additional, Maximova, Natalia, additional, Greco, Raffaella, additional, Alexander, Tobias, additional, and Snowden, John A., additional

Published
2021
Full Text
View/download PDF

10. Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

Author

Martinez-Calle, Nicolas, primary, Poynton, Edward, additional, Alchawaf, Alia, additional, Kassam, Shireen, additional, Horan, Matthew, additional, Rafferty, Mark, additional, Kelsey, Phillipa, additional, Scott, Gemma, additional, Bruce, Stephanie, additional, Buckley, Hannah, additional, Jones, Sophie, additional, Lim, Yeong Jer, additional, Loretta, Ngu, additional, Lewis, David, additional, Ajithkumar, Thankamma, additional, Culligan, Dominic J., additional, Rowntree, Clare, additional, Wright, Josh, additional, McKay, Pamela, additional, Fourali, Samih, additional, Eyre, Toby A., additional, Smith, Jeffrey, additional, Osborne, Wendy, additional, Yallop, Deborah, additional, Linton, Kim, additional, Fox, Christopher P., additional, and Cwynarski, Kate, additional

Published
2018
Full Text
View/download PDF

12. Deep Immune Profiling Identifies Novel T-Cell Subpopulations That Influence Specific Clinical Outcomes in Chronic Lymphocytic Leukaemia (CLL)

Author

Lim, Yeong Jer, Duckworth, Andrew, Clarke, Kim, Kennedy, Paul, Oates, Melanie, Gornall, Matthew, Kalakonda, Nagesh, Slupsky, Joseph, and Pettitt, Andrew

Abstract

Introduction:In chronic lymphocytic leukaemia (CLL), a dynamic interplay exists whereby CLL cells shape the immune microenvironment and perturb normal immune function while at the same time relying on non-malignant immune cells for survival and proliferation signals. However, it is unclear to what extent different T-cell populations vary among individual CLL patients and whether such variation influences the occurrence of specific clinical events. To address this knowledge gap, pre-treatment blood samples obtained from patients enrolled in a large clinical trial of frontline therapy were subjected to deep immune phenotyping by mass cytometry and the results related with clinical outcomes.

Published
2023
Full Text
View/download PDF

13. Immunomodulatory Effects of Chemo-Immunotherapy ± Idelalisib in Chronic Lymphocytic Leukaemia (CLL)

Author

Lim, Yeong Jer, Duckworth, Andrew, Clarke, Kim, Oates, Melanie, Gornall, Matthew, Kalakonda, Nagesh, Slupsky, Joseph, and Pettitt, Andrew

Abstract

Introduction:Chronic lymphocytic leukaemia (CLL) is characterised by a dysfunctional immune profile. However, the precise impact of therapy on this altered immune state, both short and long term, remains unclear. The collection of pre-treatment and longitudinal blood samples in the NCRI phase III RIAltO trial (NCT01678430) offered a unique opportunity to address this question in the context of frontline chemo-immunotherapy (CIT) containing bendamustine or chlorambucil. The factorial randomisation to idelalisib versus placebo also provided a framework for investigating the immunomodulatory effects of PI3Kδ inhibition in this setting.

Published
2023
Full Text
View/download PDF

14. Contributors

Author

Abdelkader, Amany, Allison, Kim, Barbagallo, Michael Salvatore, Bridge, Nick, Carr, Bethany, Fenwick, Clare, Fraser, Angela, Haywood, Peter, Kapp, Susanne, Laing, Erin, Lee, Michael, Lim, Yeong Jer, Macdiarmid, Rachel, McDonald, Elissa M, Montayre, Jed, Moore, Sonya, Nayagam, Bryony A, Nayagam, David AX, Nelson, Steven, Newall, Fiona, On, Wei Heng, Phillips, Jane, Saravanakumar, Padmapriya, Tomkins, Zerina, and Yap, Kiryu

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results